However, considering the high prevalence of nonalcoholic fatty liver disease, the presence of this morbid condition particularly in patients with ALT and AST activity in the upper part of the reference range cannot be excluded. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.